|1.||Schiffmann, Raphael: 9 articles (01/2014 - 01/2002)|
|2.||Germain, Dominique P: 8 articles (05/2015 - 07/2005)|
|3.||Desnick, Robert J: 8 articles (05/2015 - 06/2002)|
|4.||Auray-Blais, Christiane: 7 articles (07/2015 - 03/2008)|
|5.||Branch, Donald R: 7 articles (03/2013 - 09/2005)|
|6.||Warnock, David G: 6 articles (12/2015 - 09/2006)|
|7.||Jung, Sung-Chul: 6 articles (10/2015 - 09/2009)|
|8.||Lockhart, David J: 6 articles (07/2015 - 01/2010)|
|9.||Clarke, Joe T R: 6 articles (12/2013 - 03/2007)|
|10.||Rozenfeld, Paula A: 6 articles (05/2013 - 09/2006)|
|1.||Fabry Disease (Fabry's Disease)
07/01/2012 - "Assessing the amount of globotriaosylceramide inclusions in renal peritubular capillaries by a semiquantitative approach is a standard and useful measure of therapeutic efficacy in Fabry disease, achievable by light microscopy analysis. "
12/01/2010 - "We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. "
03/01/2005 - "The aim of this study was to determine whether globotriaosylceramide (Gb3) is a useful biomarker in Fabry disease. "
12/01/2015 - "Nephropathy is an important feature of classical Fabry disease, which results in alpha-galactosidase A deficiency and cellular globotriaosylceramide accumulation. "
05/06/2015 - "Globotriaosylsphingosine (lyso-Gb3), a deacylated form of globotriaosylceramide (Gb3), has emerged as a marker of Fabry disease. "
10/01/2004 - "At 2 years their pain scores had improved but this was not accompanied by any reduction in the plasma or urine globotriaosylceramide levels. "
07/05/2001 - "We also evaluated the histologic clearance of microvascular endothelial deposits of globotriaosylceramide in the endomyocardium and skin, as well as changes in the level of pain and the quality of life. "
07/01/2013 - "Health state, pain levels, sweat volume and latency and plasma and urinary globotriaosylceramide levels were recorded throughout the study. "
01/01/2007 - "Also, no differences in glomerular filtration rate, pain and decline in globotriaosylceramide levels were found. "
05/01/2010 - "In treated boys, there were sustained, statistically-significant improvements in the clinical features of Fabry disease, including reduced plasma globotriaosylceramide levels, reduced pain severity assessed by the Brief Pain Index, and improved heart rate variability. "
|3.||Neuralgia (Stump Neuralgia)
12/01/2012 - "Ten RCTs were identified, which showed improvements in neuropathic pain, in heart abnormalities and in globotriaosylceramide (GL-3) levels. "
10/01/2012 - "Although the change in myocardial globotriaosylceramide content (primary endpoint in one study) did not significantly differ between agalsidase alfa and placebo recipients, the change in the Brief Pain Inventory (BPI) 'pain at its worst' score (reflecting neuropathic pain while without pain medications; primary endpoint in the second study) was improved to a significantly greater extent with agalsidase alfa than with placebo. "
|4.||Peripheral Nervous System Diseases (PNS Diseases)
|5.||Burkitt Lymphoma (Burkitt's Lymphoma)
10/01/2014 - "SAL, catfish (Silurus asotus) egg RBL composed of three domains, binds to Burkitt's lymphoma Raji cells through globotriaosylceramide (Gb3) carbohydrate chain and to reduce cell size and growth by altering membrane composition without causing cell death. "
07/01/2001 - "Furthermore, the purified Stx1 B subunit was able to bind specifically to Gb3Cer expressed on Burkitt's lymphoma cells. "
04/01/1997 - "Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells."
05/01/1991 - "We have previously reported that a neutral glycolipid (globotriosylceramide; Gb3) was specifically expressed on Burkitt's lymphoma cells and on a subset of germinal center tonsillar B lymphocytes. "
12/01/1989 - "Decreased accessibility of globotriaosylceramide associated with decreased tumorigenicity in Burkitt's lymphoma variants induced by immunoselection."
|7.||Protein Isoforms (Isoforms)
|8.||Biological Markers (Surrogate Marker)
|9.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|1.||Enzyme Replacement Therapy
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Drug Therapy (Chemotherapy)